Abstract: The invention provides for a fusion protein comprising a 3E10 Fv joined to a Hsp-70, Hsp-27, Hsp-90 or GRP-78 or portion thereof, and optionally, the 3E10 Fv comprising an amino acid sequence AGIH at its amino terminus.
Type:
Grant
Filed:
March 15, 2013
Date of Patent:
August 15, 2017
Assignee:
The United States of America as represented by the Department of Veterans Affairs
Inventors:
Robert N. Nishimura, Richard H. Weisbart, James Hansen
Abstract: Isolated or recombinant anti-HER3 monoclonal antibodies are provided. In some cases, antibodies of the embodiments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer.
Type:
Grant
Filed:
March 13, 2014
Date of Patent:
August 8, 2017
Assignee:
THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
Abstract: The present invention relates to fibronectin based scaffold domain protein that bind interleukin 23 (IL-23), specifically the p19 subunit of IL-23. The invention also relates to the use of the innovative proteins in therapeutic applications to treat autoimmune diseases. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.
Type:
Grant
Filed:
November 25, 2014
Date of Patent:
July 25, 2017
Assignee:
Bristol-Myers Squibb Company
Inventors:
Ruchira Dasgupta, Alex Bush, Lumelle Schneeweis, Linda Engle
Abstract: Disclosed are CD70 binding agents, such as humanized anti-CD70 antibodies and fragments and derivatives, that exert a cytotoxic, cytostatic or immunomodulatory on CD70 expressing cells, as well as pharmaceutical compositions and kits comprising the antibody, fragment or derivative. Also disclosed are methods for the treatment of CD70-expressing cancers and immunological disorders, comprising administering to a subject the CD70 binding agents or pharmaceutical compositions.
Abstract: The present disclosure relates to a bispecific single chain antibody which has a first binding domain specifically binding to human CD3, and a second binding domain specifically binding to human CEA, where the second binding domain comprises at least a part of the CDR-H3 or the complete CDR-H3 of murine monoclonal antibody A5B7, a pharmaceutical composition comprising the bispecific single chain antibody, and methods for the treatment of an epithelial tumor in a human with the pharmaceutical compositions containing the bispecific single chain antibody. Furthermore, processes for the production of the pharmaceutical compositions as well as medical/pharmaceutical uses for the specific bispecific single chain antibody molecules bearing specificities for the human CD3 antigen and the human CEA antigen are disclosed.
Type:
Grant
Filed:
January 14, 2013
Date of Patent:
July 4, 2017
Assignee:
AMGEN RESEARCH (MUNICH) GMBH
Inventors:
Ralf Lutterbüse, Petra Fluhr, Evelyne Schaller, Doris Rau, Susanne Mangold, Peter Kufer, Alexander Murr, Tobias Raum, Monika Wissinger
Abstract: Provided are methods for optimizing therapy of, treating a patient having, or selecting (identifying) patients who will benefit from treatment for, a cancer (e.g., a non-hematological cancer; e.g., a gynecological cancer). The methods comprise determining whether the patient will benefit from treatment with an ErbB3 inhibitor (e.g., an anti-ErbB3 antibody), with or without either a taxane or an aromatase inhibitor, or with a taxane or an aromatase inhibitor in the absence of an ErbB3 inhibitor, based on levels of particular biomarkers and combinations of biomarkers measured in a biological sample obtained from the patient. The methods further comprise optimizing the patient's therapy, selecting the patient for treatment, or treating the patient accordingly. In various aspects the biological samples are sections of a biopsy (e.g., a formalin fixed paraffin embedded biopsy). In other aspects the biomarkers are proteins and/or nucleic acids.
Type:
Grant
Filed:
December 10, 2015
Date of Patent:
June 27, 2017
Assignee:
Merrimack Pharmaceuticals, Inc.
Inventors:
Bambang Adiwijaya, Akos Czibere, William Kubasek, Gavin MacBeath, Sharon Moulis, Rachel C. Nering, Lin Nie, Defne Yarar
Abstract: The present inventors succeeded in improving the antibody constant region to have increased stability under acid conditions, reduced heterogeneity originated from disulfide bonds in the hinge region, reduced heterogeneity originated from the H chain C terminus, and increased stability at high concentrations as well as in discovering novel constant region sequences having reduced Fc? receptor-binding, while minimizing the generation of novel T-cell epitope peptides. As a result, the present inventors successfully discovered antibody constant regions with improved physicochemical properties (stability and homogeneity), immunogenicity, safety, and pharmacokinetics.
Abstract: The invention relates to an antigen binding site for binding to a P2X7 receptor, the antigen binding site being defined by general formula 1: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4.
Type:
Grant
Filed:
March 27, 2015
Date of Patent:
June 27, 2017
Assignee:
BIOSCEPTRE (AUST) PTY LTD
Inventors:
Julian Alexander Barden, Neil Brewis, Philip Jones, Steven Grant
Abstract: One aspect of the present disclosure provides antibodies that can act as agonists of PD-1, thereby modulating immune responses regulated by PD-1. Another aspect of the disclosure provides compositions comprising PD-1 specific antibodies and their use in methods of down regulating the immune response. These methods can be practiced on any subject, including humans or animals. Anti-PD-1 antibodies disclosed herein may be used, in another aspect of the invention to detect PD-1 or its fragments in a biological sample. The amount of PD-1 detected may be correlated with the expression level of PD-1, and associated with the activation status of immune cells (e.g., activated T cells, B cells, and/or monocytes) in the subject.
Abstract: The present invention relates to particularly stable and soluble scFv antibodies and Fab fragments specific for TNF?, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF?, and low immunogenicity. Said antibodies are designed for the diagnosis and/or treatment of TNF?-related disorders. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.
Type:
Grant
Filed:
March 8, 2016
Date of Patent:
June 20, 2017
Assignee:
ESBATech, an Alcon Biomedical Research Unit LLC
Inventors:
Stefan Ewert, David Urech, Adrian Auf Der Maur, Alcide Barberis, Peter Lichtlen
Abstract: The present disclosure relates to the antibody engineering field and, more particularly, to a process for the screening of antibodies and/or the modulation of the agonistic/antagonistic activity of antibodies. More particularly, the disclosure concerns a process of improving the antagonistic activity of a monoclonal antibody directed against a specific target molecule, or a divalent functional fragment or derivative thereof, the antibody being capable of inhibiting one or more of the biological activities of the target molecule, wherein the process comprises a stage of reconfiguration of the hinge region consisting of a modification of the amino acid sequence of the hinge region by the deletion, the addition or the substitution of at least one amino acid. The disclosure also relates to polypeptides useful for such a modulation method and the obtained antibodies.
Abstract: Anti-TAT226 antibodies and immunoconjugates thereof are provided. Methods of using anti-TAT226 antibodies and immunoconjugates thereof are provided.
Abstract: Proteins that bind IL-17 and/or IL-17F are described along with their use in composition and methods for treating, preventing, and diagnosing IL-17 related diseases and for detecting IL-17 in cells, tissues, samples, and compositions.
Type:
Grant
Filed:
April 25, 2014
Date of Patent:
May 30, 2017
Assignee:
ABBVIE INC.
Inventors:
Chung-Ming Hsieh, Margaret Hugunin, Anwar Murtaza, Bradford L. McRae, Yuliya Kutskova, John E. Memmott, Jennifer M. Perez, Suju Zhong, Edit Tarcsa, Anca Clabbers, Craig Wallace, Shaughn H. Bryant, Mary R. Leddy
Abstract: This invention provides compositions and methods to treat a condition or disease without the use of exogenous targeting sequences or chemical compositions. The present invention relates to single-domain antibodies (sdAbs), proteins and polypeptides comprising the sdAbs that are directed against intracellular components that cause a condition or disease. The invention also includes nucleic acids encoding the sdAbs, proteins and polypeptides, and compositions comprising the sdAbs. The invention includes the use of the compositions, sdAbs, and nucleic acids encoding the sdAbs for prophylactic, therapeutic or diagnostic purposes.
Abstract: Disclosed herein are methods for identifying a subject as having NSCLC that is predicted or is likely to respond to treatment with an ALK inhibitor, for example crizotinib. The methods include identifying a sample including NSCLC tumor cells as ALK-positive or ALK-negative using immunohistochemistry (IBC) and scoring methods disclosed herein. A subject is identified as having NSCLC likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-positive and is identified as having NSCLC not likely to respond to treatment with an ALK inhibitor if the sample is identified as ALK-negative. According to certain embodiments of the methods, subjects predicted to respond to an ALK inhibitor may then be treated with an ALK inhibitor such as crizotinib.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
May 16, 2017
Assignee:
Ventana Medical Systems, Inc.
Inventors:
Thomas Grogan, Michael Barnes, June Clements, Hiro Nitta, Esteban Roberts, Crystal Schemp, Shalini Singh, Penny Towne
Abstract: Sulfated glycoproteins, and methods of making and using such sulfated glycoproteins, are described.
Type:
Grant
Filed:
May 18, 2012
Date of Patent:
May 16, 2017
Assignee:
Momenta Pharmaceuticals, Inc.
Inventors:
Dorota A. Bulik, Carlos J. Bosques, Brian Edward Collins, Maurice Gaston Hains, Nathaniel J. Washburn, James Meador, Sean Smith, Naveen Bhatnagar
Abstract: Disclosed herein are immunoglobulin constructs comprising at least one immunoglobulin domain or fragment thereof; and a therapeutic polypeptide or derivative or variant thereof attached to or inserted into said immunoglobulin domain. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a knob domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said knob domain of the CDR3H. Also provided are immunoglobulin constructs comprising a mammalian immunoglobulin heavy chain comprising at least a portion of a stalk domain in the complementarity-determining region 3 (CDR3H) or fragment thereof; and a therapeutic polypeptide attached to or inserted into said stalk domain of the CDR3H. Also described herein are methods and compositions comprising the immunoglobulin constructs described herein for treatment and prevention of a disease or condition in a subject.
Type:
Grant
Filed:
January 10, 2014
Date of Patent:
May 9, 2017
Assignee:
THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH
Inventors:
Feng Wang, Yong Zhang, Peter G. Schultz
Abstract: An antibody against mutant ?-actinin-4 having an amino acid sequence with at least one amino acid residue substitution in the region between position 245 and 263 in the amino acid sequence of ?-actinin-4, wherein the antibody recognizes all or a part of the substituted amino acid residue(s) in the region.
Type:
Grant
Filed:
September 9, 2011
Date of Patent:
May 9, 2017
Assignees:
TRANS GENIC INC., NATIONAL CANCER CENTER
Abstract: Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-Müllerian hormone type II receptor.
Type:
Grant
Filed:
March 16, 2015
Date of Patent:
May 2, 2017
Assignees:
LABORATOIRE FRANCAIS DU FRACTIONNEMENT ET DES BIOTECHNOLOGIES, UNIVERSITE MONTPELLIER I, CENTRE NATIONAL DE LUTTE CONTRE LE CANCER, I.N.S.E.R.M. (Institut National de la Sante et de la Recherche Medicale)
Inventors:
Christian Behrens, Isabelle Navarro-Teulon
Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
Type:
Grant
Filed:
March 12, 2013
Date of Patent:
May 2, 2017
Assignee:
BIONTECH AG
Inventors:
Ugur Sahin, Özlem Türeci, Michael Koslowski